Key result
A 36-year-old man developed neuroleptic malignant syndrome associated with the use of quetiapine, venlafaxine, and methadone.
Case Report (n=1)
Highlights a rare case of neuroleptic malignant syndrome associated with the combined use of quetiapine, venlafaxine, and methadone.
NMS may occur with quetiapine, venlafaxine, and methadone; case report leaves open confirmation of causality and incidence.
We report a case of neuroleptic malignant syndrome (NMS) in a 36-year-old man prescribed quetiapine, venlafaxine and methadone. NMS is a rare but potentially fatal side-effect of all antipsychotic medications characterized by fever and muscle rigidity, and two or more of diaphoresis, dysphagia, tremor, incontinence, changes in level of consciousness, mutism, autonomic dysfunction, leukocytosis and elevated creatine kinase. Complications include rhabdomyolysis, renal failure and death. Mortality appears to be reduced with second-generation antipsychotics. Although predominantly associated with antipsychotic use, NMS has been observed with antidepressants and lithium.
No takes yet. Share an insight, caveat, or question.
Woods et al. (2012) conducted a case report in Neuroleptic malignant syndrome (n=1). Quetiapine, venlafaxine, and methadone was evaluated on Neuroleptic malignant syndrome. A 36-year-old man developed neuroleptic malignant syndrome associated with the use of quetiapine, venlafaxine, and methadone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: